Merit Medical(MMSI) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported total revenue of $393.9 million for Q4 2025, an 11% increase year-over-year on a GAAP basis and a 10% increase on a constant currency basis [6][7] - Non-GAAP operating margin increased by 138 basis points year-over-year to 21% [7][18] - Non-GAAP EPS grew by 12%, exceeding expectations, with Q4 net income at $62.5 million or $1.04 per share, compared to $56.3 million or $0.93 per share in the prior period [8][18] - Free cash flow for Q4 was $74 million, a 13% increase year-over-year, marking a quarterly record for the company [8][19] Business Line Data and Key Metrics Changes - Total revenue growth in Q4 was driven by a 9% increase in the cardiovascular segment and a 15% increase in the endoscopy segment [10] - Cardiac Intervention product sales increased by 21%, while Peripheral Intervention products sales increased by 13% [12][13] - Sales of custom procedural solutions products increased by 4%, driven by high teens growth in kit sales [14] Market Data and Key Metrics Changes - U.S. sales increased by 12% year-over-year, while international sales increased by 6% [16] - U.S. organic constant currency sales growth was 8%, while international organic constant currency sales growth was 4% [16] Company Strategy and Development Direction - The company aims for solid constant currency growth and non-GAAP operating margin expansion for 2026, with a focus on executing its Continued Growth Initiatives program [9][10] - The divestiture of the DualCap product line is expected to create additional manufacturing capacity and free up resources for higher-margin products [24][38] - The company is prioritizing research and development efforts and is open to strategic M&A to enhance its competitive position [38] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the dynamic global macro environment but expressed confidence in the company's execution and financial targets [9][10] - The CEO emphasized the importance of a listening tour to gather feedback and enhance the company's foundation for success [30][31] - The company is optimistic about its future based on strong product innovation and strategic acquisitions [36][38] Other Important Information - The company generated nearly $216 million of free cash flow in 2025, up 16% year-over-year, exceeding guidance expectations [19][20] - The balance sheet as of December 31, 2025, showed cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million [21] Q&A Session Summary Question: What are the additional gross margin drivers for the company? - Management highlighted the focus on product mix, pricing, cost discipline, and ongoing SKU rationalization as key drivers for gross margin improvement [42][44][45] Question: How is the WRAPSODY product performing in the outpatient setting? - Management acknowledged that initial revenue expectations for WRAPSODY were missed but expressed confidence in achieving the $7 million revenue target for 2026 [46][48][49] Question: What factors are influencing the guidance for free cash flow in 2026? - Management indicated that the guidance reflects a conservative approach, considering ongoing capital expenditures and timing-related factors [52][54] Question: What areas is the company looking at for potential M&A? - The company is focusing on both foundational and therapeutic products, seeking strategic opportunities that align with its growth drivers [56][57][59] Question: What is the outlook for the OEM business? - Management noted that the OEM business is expected to normalize to mid-to-high single-digit growth, despite recent inventory destocking [62][63] Question: What are the expectations for growth in China? - Management indicated that growth in China was down year-over-year, primarily due to volume-based purchasing impacts, but remains optimistic about future improvements [78][79]